Sina Habibi, Co-founder & CEO of Cognetivity Neurosciences (CSE: CGN) sits down with us today to discuss recent advancements in Alzheimer’s drugs, treatments and screening processes. We then transition into a discussion on Cognetitivty, including their main production offering, its involvement in the delivery of Alzheimer’s drugs, recent collaborations and agreements as well as what to watch for in the near term.
Cognetivity is a tech firm that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Through the use of AI and machine learning, the tech is able to detect the early onset of Alzheimer’s and dementia through testing the performance of large areas of the brain. The tech has acquired regulatory approval for use in both the UK and Europe, with further approvals in North America anticipated to occur.
FULL DISCLOSURE: Cognetivity Neurosciences is a former client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cognetivity Neurosciences. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.